Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1958 1
1959 1
1962 1
1965 1
1966 1
1967 1
1968 1
1969 3
1970 3
1972 2
1973 3
1974 2
1975 5
1976 4
1977 2
1978 1
1979 3
1980 2
1981 1
1982 4
1984 4
1985 2
1986 4
1987 3
1988 6
1990 5
1991 3
1992 7
1993 7
1994 1
1995 3
1997 8
1998 5
1999 6
2000 9
2001 7
2002 5
2003 8
2004 8
2005 12
2006 6
2007 10
2008 13
2009 12
2010 7
2011 19
2012 15
2013 20
2014 14
2015 17
2016 22
2017 14
2018 15
2019 17
2020 29
2021 25
2022 24
2023 21
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

407 results

Results by year

Filters applied: . Clear all
Page 1
Advances in the understanding and treatment of sepsis-induced immunosuppression.
Venet F, Monneret G. Venet F, et al. Nat Rev Nephrol. 2018 Feb;14(2):121-137. doi: 10.1038/nrneph.2017.165. Epub 2017 Dec 11. Nat Rev Nephrol. 2018. PMID: 29225343 Review.
Scientific advances have highlighted the role of metabolic failure, epigenetic reprogramming, myeloid-derived suppressor cells, immature suppressive neutrophils and immune alterations in primary lymphoid organs (the thymus and bone marrow) in sepsis. An improved understand …
Scientific advances have highlighted the role of metabolic failure, epigenetic reprogramming, myeloid-derived suppressor cells, immature sup …
Update on the clinical management of multiple endocrine neoplasia type 1.
Pieterman CRC, Valk GD. Pieterman CRC, et al. Clin Endocrinol (Oxf). 2022 Oct;97(4):409-423. doi: 10.1111/cen.14727. Epub 2022 Apr 1. Clin Endocrinol (Oxf). 2022. PMID: 35319130 Free PMC article. Review.
For duodenopancreatic neuroendocrine tumours (NETs), the main challenge is accurate and individualized risk stratification to enable personalized surveillance and treatment. Thymus NETs remain one of the most aggressive MEN1-related tumours. ...Pituitary adenomas are most …
For duodenopancreatic neuroendocrine tumours (NETs), the main challenge is accurate and individualized risk stratification to enable persona …
The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions.
Dvorak CC, Haddad E, Heimall J, Dunn E, Buckley RH, Kohn DB, Cowan MJ, Pai SY, Griffith LM, Cuvelier GDE, Eissa H, Shah AJ, O'Reilly RJ, Pulsipher MA, Wright NAM, Abraham RS, Satter LF, Notarangelo LD, Puck JM. Dvorak CC, et al. J Allergy Clin Immunol. 2023 Feb;151(2):539-546. doi: 10.1016/j.jaci.2022.10.022. Epub 2022 Nov 28. J Allergy Clin Immunol. 2023. PMID: 36456361 Free PMC article.
Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics.
Ahmed Z, Afridi SS, Shahid Z, Zamani Z, Rehman S, Aiman W, Khan M, Mir MA, Awan FT, Anwer F, Iftikhar R. Ahmed Z, et al. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):e865-e875. doi: 10.1016/j.clml.2021.06.012. Epub 2021 Jun 24. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34330673 Review.
The annual incidence of PMBCL is 0.4 per million with a 5-year survival rate exceeding 70% with improving supportive care and genetic characterization of the disease. Pathogenesis involves dysregulation of Janus kinase-signal transducer and activator of transcription (JAK- …
The annual incidence of PMBCL is 0.4 per million with a 5-year survival rate exceeding 70% with improving supportive care and genetic …
Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement.
Niederle B, Selberherr A, Bartsch DK, Brandi ML, Doherty GM, Falconi M, Goudet P, Halfdanarson TR, Ito T, Jensen RT, Larghi A, Lee L, Öberg K, Pavel M, Perren A, Sadowski SM, Tonelli F, Triponez F, Valk GD, O'Toole D, Scott-Coombes D, Thakker RV, Thompson GB, Treglia G, Wiedenmann B. Niederle B, et al. Neuroendocrinology. 2021;111(7):609-630. doi: 10.1159/000511791. Epub 2020 Sep 24. Neuroendocrinology. 2021. PMID: 32971521 Free article. Review.
Duodenopancreatic neuroendocrine neoplasias (DP-NENs) are still the second most common manifestation in MEN1 and, besides NENs of the thymus, remain a leading cause of death. DP-NENs are thus of main interest in the effort to reevaluate recommendations for their diagnosis …
Duodenopancreatic neuroendocrine neoplasias (DP-NENs) are still the second most common manifestation in MEN1 and, besides NENs of the thy …
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up().
Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Baudin E, et al. Ann Oncol. 2021 Apr;32(4):439-451. doi: 10.1016/j.annonc.2021.01.003. Epub 2021 Jan 19. Ann Oncol. 2021. PMID: 33482246 Free article. No abstract available.
Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors.
Xu C, Zhang Y, Wang W, Wang Q, Li Z, Song Z, Wang J, Yu J, Liu J, Zhang S, Cai X, Wu M, Zhan P, Liu H, Lv T, Miao L, Min L, Li J, Liu B, Yuan J, Jiang Z, Lin G, Chen X, Pu X, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Guo H, Chu Q, Meng R, Liu X, Wu J, Hu X, Fang M, Zhou J, Zhu Z, Chen X, Pan W, Pang F, Zhou Y, Jian Q, Wang K, Wang L, Zhu Y, Yang G, Lin X, Cai J, Liang L, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Huang J, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Hao Y, Wang Z, Wan B, Lv D, Yu G, Li A, Kang J, Zhang J, Zhang C, Chen H, Shi L, Ye L, Wang G, Wang Y, Gao F, Zhou W, Hu C, Wei J, Li B, Li Z, Li Y, Liu Z, Yang N, Wu L, Wang Q, Huang W, Hong Z, Wang G, Fang M, Fang Y, Zhu X, Du K, Ji J, Shen Y, Zhang Y, Ma S, Song Y, Lu Y, Liu A, Fang W, Zhong W. Xu C, et al. Thorac Cancer. 2023 Apr;14(12):1102-1117. doi: 10.1111/1759-7714.14847. Epub 2023 Mar 16. Thorac Cancer. 2023. PMID: 36924056 Free PMC article.
Treatment for advanced, unresectable TETs consist mainly of radiotherapy and chemotherapy, but there is a lack of standard first- and second-line treatment regimens. Recently, targeted therapies and immune checkpoint inhibitors have shown promising outcomes in TETs. Based …
Treatment for advanced, unresectable TETs consist mainly of radiotherapy and chemotherapy, but there is a lack of standard first- and second …
Pathophysiology and human cancer risk assessment of pharmaceutical-induced thymoma in carcinogenicity studies.
Radi ZA, Khan N. Radi ZA, et al. Toxicol Appl Pharmacol. 2023 May 1;466:116471. doi: 10.1016/j.taap.2023.116471. Epub 2023 Mar 17. Toxicol Appl Pharmacol. 2023. PMID: 36934859 Review.
Potential non-genotoxic mechanisms that might contribute to the pathogenesis of thymoma development in one sex (female) Wistar Han rats include: (1) hormonal differences, (2) high proliferation rate of TECs, (3) delayed physiologic thymic involution, and/or (4) significant level …
Potential non-genotoxic mechanisms that might contribute to the pathogenesis of thymoma development in one sex (female) Wistar Han rats incl …
Thymoma: Diagnosis and treatment.
Singh G, Rumende CM, Amin Z. Singh G, et al. Acta Med Indones. 2011 Jan;43(1):74-8. Acta Med Indones. 2011. PMID: 21339550 Review.
For inoperable patients, induction chemotherapy followed by a surgical reassessment post-therapy, and adjuvant radiation therapy is generally recommended, in spite of the lacking prospective studies for such treatment. Durable responses can be obtained both in the m …
For inoperable patients, induction chemotherapy followed by a surgical reassessment post-therapy, and adjuvant radiation therapy …
Management of thymomas.
Wright CD. Wright CD. Crit Rev Oncol Hematol. 2008 Feb;65(2):109-20. doi: 10.1016/j.critrevonc.2007.04.005. Epub 2007 Jun 14. Crit Rev Oncol Hematol. 2008. PMID: 17570676 Review.
Multimodality therapy can result in long-term disease-free survival for patients presenting with locally advanced disease. Thymomas are sensitive to both chemotherapy and radiation therapy and are utilized with good effects in unresectable patients....
Multimodality therapy can result in long-term disease-free survival for patients presenting with locally advanced disease. Thymomas a …
407 results